Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | PGR | P06401 | 4/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518869 | 0.82 | TRPV4 (0.57) | TRPV4CYP11B1CYP11B2 | |
| SCHEMBL2639309 | 0.78 | MAOB (0.42) | TRPV4 | |
| SCHEMBL74807 | 0.76 | TRPV4 (0.46) | TRPV4ARGRM4CNR2PTP4A3 | |
| SCHEMBL4824074 | 0.76 | TRPV4 (0.31) | TRPV4 | |
| SCHEMBL27274265 | 0.76 | MAOB (0.44) | TRPV4ARGRM4CNR2PGR | |
| SCHEMBL29998893 | 0.74 | CYP2A6 (0.46) | TRPV4ARGRM4CYP11B1CYP11B2 | |
| SCHEMBL924361 | 0.74 | TRPV4 (0.45) | TRPV4ARGRM4CNR2PTP4A3 | |
| SCHEMBL481131 | 0.74 | CYP2A6 (0.46) | TRPV4ARGRM4CYP11B1CYP11B2 | |
| SCHEMBL16961256 | 0.74 | TRPV4 (0.41) | TRPV4ABCG2ARGRM4CNR2 | |
| SCHEMBL16555923 | 0.73 | TRPV4 (0.69) | TRPV4ABCG2ARGRM4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | claimed |
| EP-4100410-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| CN-115362156-A | Muscarinic receptor 4 antagonists and methods of use | 纽罗克里生物科学有限公司 | 2022-11-18 | — | — | CN | claimed |
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | claimed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| WO-2019068935-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTRUMENTS S.R.L. (IT) | 2019-04-11 | — | — | WO | claimed |
| EP-2119717-B1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2018-01-17 | — | — | EP | claimed |
| US-8697868-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | claimed |
| JP-4733058-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| EP-2119717-A1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2009-11-18 | — | — | EP | claimed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | claimed |
| EP-1758905-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2009-04-29 | — | — | EP | claimed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7501426-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-10 | — | — | US | claimed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | claimed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| EP-1758905-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2007-03-07 | — | — | EP | claimed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| WO-2005085246-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DPP INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | TRPV4 1113/4885ABCG2 134/4885AR 3000/4885 |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | TRPV4 535/4885ABCG2 660/4885AR 3330/4885 |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | TRPV4 133/4885ABCG2 670/4885AR 1161/4885 |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | TRPV4 1161/4885ABCG2 109/4885AR 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.